Biocartis to develop rapid Ebola virus triage test, 4/15

April 2015—Biocartis announced it is in the testing phase of a Rapid Ebola Virus Triage Test that it is developing in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp, Belgium, for its Idylla system, a CE-IVD-marked, fully automated molecular diagnostic platform.

The Rapid Ebola Virus Triage Test uses 0.2 mL of blood, which is added directly to the Idylla cartridge. The cartridge contains the necessary reagents onboard for performing the analysis on the company’s molecular diagnostics system. Complete analysis takes about 90 minutes and can be operated by health care professionals in most settings, including in the field, making the test suitable for use in regions with limited infrastructure.

Biocartis believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the U.S., Biocartis has registered for field testing in West Africa to gather additional clinical evidence for the test performance.

Biocartis , +32 15 632 600